Company

Novo Nordisk Opens Its Next Chapter With 'Lasting Health Starts Now' Rebrand and 'The Novo Way' Culture – Single 'Novo' Name Signals a Faster, Consumer‑Driven Era
Novo NordiskNYSE: NVO

Novo Nordisk Opens Its Next Chapter With ‘Lasting Health Starts Now’ Rebrand and ‘The Novo Way’ Culture – Single ‘Novo’ Name Signals a Faster, Consumer‑Driven Era

Novo Nordisk (NYSE: NVO) today unveiled a corporate rebrand centred on "Lasting Health Starts Now" and the single "Novo" name, together with an updated corporate culture, "The Novo Way", designed…

Sichuan Biokin's HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Sichuan Biokin’s HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Henlius' Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China's Bone Health Market

Henlius’ Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China’s Bone Health Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders
Jingyi BioYHLO Biotech

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Sanofi's Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia – Expanding Global Footprint Across Six Major Markets
NASDAQ: SNYProduct approvals

Sanofi’s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia – Expanding Global Footprint Across Six Major Markets

CancerClinical trial approval / initiation

Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody – Dual US-China Authorization for Hematological Malignancies

Ab&B Bio-TechClinical trial approval / initiation

Ab&B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine – First Dual-Approved Candidate Globally

Show More